Highlight

1. Hugedrugmarket for HBV

1）In 2016 global HBV prevalence is 3.9%, 292m cases, within which 32% cases in need therapies. In 2017, 870,000 people have been dead from HBV. 25% HBV patients develop HCC.

2）Patients receiving Long-term treatment with the current therapies are easily relapse after off-treatment. And uncleared HBsAg cause unexpected immune reaction for long time. Low functional cure rate is a big challenge for HBV therapy, and new strategies are in need to reform HBV therapy.

2. Capsid assembly inhibitors is a viablestrategy for HBV

1）Capsid assembly inhibitors bind to dimer-dimer interface and disrupt formation of functional nucleocapsids, blocking several steps of HBV life cycle including entry, replication, assembly and secretion and preventing maturation of infectious viral particles.

3. A second general capsid assembly inhibitor with better anti-HBV activity than contemporary competitors in vitro.

1）The EC50 and EC90 of asset are both at nanomolar lever, which are 10 – 100 times lower than that of competitors(AB-506, JNJ-379, NVR3-778 and HBI-0731) in vitro.

2）Asset shows a more potently inhibition of HBV replication, especially HBeAg and HBsAg in PHH infection model, comparing with ETV.

3. Excellent active HBV ability in vivo.

1) In HDI mouse model, asset shows a dose dependently reduction of serum and liver HBV DNA, illustrating an excellent antiviral activity.

2）Asset is more potent reducing the viral antigen in vivo.

4. Goodsafety.

1）Low CYP enzyme induction in preclinical study.

The combination of asset and ETV in phase IIb study accelerated HBV 2）High safety window remains greater opportunity for curative combination therapy, which strategy is high up the functional cure rate.

Research progress：

1. Phase 1 trial is on-going;

2. Excellent antiviral effect in vitro and in vivo;

3. Largesafety window, suit for combination therapy.